Trial Profile
A Study to Evaluate the Predictive Factors for Significant Clinical Worsening after Natalizumab Withdrawal in Multiple Sclerosis (MS) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 25 Feb 2016 New trial record